AACR Annual Meeting 2025, Chicago, IL, April 25-30

‍

genOway’s program at the American Association for Cancer Research Annual Meeting 2025

‍

‍

‍

🔬 Spotlight Theater presentation

Tuesday, April 29, 2025 | 3 pm - Spotlight Theater E

Title: "Assessment of translational tumor biology, and biologic's efficacy and safety in preclinical humanized models"‍

Presenter: Kader Thiam, CSO & SVP – Discovery, Preclinical Models & Services

Presentation highlights:

• genO-BRGSF-HIS mouse is a tool to assess the efficacy and safety of immunotherapies targeting lymphoid and myeloid cellsgenO-BRGSF-HIS mouse
• TME in genO-BRGSF-HIS mice is shaped by tumor type and tumor burden
• genO-hFcγR model represents an alternative to genO-BRGSF-HIS to evaluate compounds working through Fc-mediated functions

‍

‍

📰 Poster presentations

‍
⮞ Tumor cell line-derived xenograft subtype shapes tumor microenvironment composition in genO-BRGSF-HIS mice | Download poster here

• Human CD47 and SIRPα expression patterns recapitulate the murine expression of CD47 and SIRPα in genO-hCD47/hSIRPα model
• Efficacy and safety of CD47- and/or SIRPα-targeting agents can be assessed in the genO-hCD47/hSIRPα model
• genO-hCD47/hSIRPα model is suitable for biodistribution assay for non-invasive in vivo imaging of tumors

⮞ Preclinical double-humanized genO-hCD47/hSIRPα mouse model and MC38 cell line expressing human CD47 for efficacy and safety assessment of anti-CD47/SIRPα-targeting therapies | Download poster here

• ‍genO-BRGSF-HIS mouse is permissive to cell line xenograft engraftment
• TME composition and cell polarization evolve with tumor burden and depend on tumor type in genO-BRGSF-HIS mouse
• genO-BRGSF-HIS mouse model is a valuable tool to investigate mechanism of action of immunotherapies

‍
⮞ Functional γδ T cells in genO-BRGSF-HIS mice | Download poster here

• γδ T cells develop in genO-BRGSF-HIS mice and can be expanded ex vivo and in vivo using Vγ9 expanders
• γδ T cells are recruited into the TME of tumor-bearing genO-BRGSF-HIS mice
• genO-BRGSF-HIS model brings a new perspective to evaluate therapies designed to expand and activate γδ T cells‍
  

‍
⮞ genO-hCCR8/hCCL1 humanized model for efficacy assessment of CCR8/CCL1-targeting therapies | Download poster here

• Humanization of both CCR8 and CCL1 is required for a functional axis and does not alter immune cell distribution in genO-hCCR8/hCCL1 compared to WT mice
• CCR8-targeting therapies can be assessed in genO-hCCR8/hCCL1 model
• Human-like expression pattern of CCR8 in genO-BRGSF-HIS naïve Tregs makes it a more suitable model for safety and PD assessment